Progress and prognosis in juvenile dermatomyositis

Jeffrey A. Dvergsten, Ann M. Reed

Research output: Contribution to journalArticle

Abstract

With the advent of corticosteroids as a treatment option for autoimmune disease in the early 1960s, the course of juvenile dermatomyositis was altered from one of high mortality to one with various degrees of morbidity. Prior to treatment with corticosteroids, juvenile dermatomyositis resulted in recovery, recovery with chronic disability or death. Corticosteroids significantly decreased mortality and by modifying disease course, morbidity but introduced additional complications. Biomarkers of disease activity, as well as predictors of disease course and severity, are lacking but are a focus of current investigation. Improved understanding of pathogenesis has expanded medication choices to treat both new-onset and refractory disease. Published consensus treatment plans are being implemented, facilitating studies of comparative effectiveness and toxicity.

Original languageEnglish (US)
Pages (from-to)567-584
Number of pages18
JournalInternational Journal of Clinical Rheumatology
Volume9
Issue number6
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Adrenal Cortex Hormones
Morbidity
Mortality
Autoimmune Diseases
Biomarkers
Juvenile dermatomyositis

Keywords

  • biomarkers
  • consensus treatment plans
  • corticosteroids
  • morbidity
  • mortality
  • pathogenesis
  • refractory disease

ASJC Scopus subject areas

  • Rheumatology

Cite this

Progress and prognosis in juvenile dermatomyositis. / Dvergsten, Jeffrey A.; Reed, Ann M.

In: International Journal of Clinical Rheumatology, Vol. 9, No. 6, 01.12.2014, p. 567-584.

Research output: Contribution to journalArticle

Dvergsten, Jeffrey A. ; Reed, Ann M. / Progress and prognosis in juvenile dermatomyositis. In: International Journal of Clinical Rheumatology. 2014 ; Vol. 9, No. 6. pp. 567-584.
@article{9f8a24a6f2924fd7b761d537782c543d,
title = "Progress and prognosis in juvenile dermatomyositis",
abstract = "With the advent of corticosteroids as a treatment option for autoimmune disease in the early 1960s, the course of juvenile dermatomyositis was altered from one of high mortality to one with various degrees of morbidity. Prior to treatment with corticosteroids, juvenile dermatomyositis resulted in recovery, recovery with chronic disability or death. Corticosteroids significantly decreased mortality and by modifying disease course, morbidity but introduced additional complications. Biomarkers of disease activity, as well as predictors of disease course and severity, are lacking but are a focus of current investigation. Improved understanding of pathogenesis has expanded medication choices to treat both new-onset and refractory disease. Published consensus treatment plans are being implemented, facilitating studies of comparative effectiveness and toxicity.",
keywords = "biomarkers, consensus treatment plans, corticosteroids, morbidity, mortality, pathogenesis, refractory disease",
author = "Dvergsten, {Jeffrey A.} and Reed, {Ann M.}",
year = "2014",
month = "12",
day = "1",
doi = "10.2217/ijr.14.46",
language = "English (US)",
volume = "9",
pages = "567--584",
journal = "Future Rheumatology",
issn = "1758-4272",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Progress and prognosis in juvenile dermatomyositis

AU - Dvergsten, Jeffrey A.

AU - Reed, Ann M.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - With the advent of corticosteroids as a treatment option for autoimmune disease in the early 1960s, the course of juvenile dermatomyositis was altered from one of high mortality to one with various degrees of morbidity. Prior to treatment with corticosteroids, juvenile dermatomyositis resulted in recovery, recovery with chronic disability or death. Corticosteroids significantly decreased mortality and by modifying disease course, morbidity but introduced additional complications. Biomarkers of disease activity, as well as predictors of disease course and severity, are lacking but are a focus of current investigation. Improved understanding of pathogenesis has expanded medication choices to treat both new-onset and refractory disease. Published consensus treatment plans are being implemented, facilitating studies of comparative effectiveness and toxicity.

AB - With the advent of corticosteroids as a treatment option for autoimmune disease in the early 1960s, the course of juvenile dermatomyositis was altered from one of high mortality to one with various degrees of morbidity. Prior to treatment with corticosteroids, juvenile dermatomyositis resulted in recovery, recovery with chronic disability or death. Corticosteroids significantly decreased mortality and by modifying disease course, morbidity but introduced additional complications. Biomarkers of disease activity, as well as predictors of disease course and severity, are lacking but are a focus of current investigation. Improved understanding of pathogenesis has expanded medication choices to treat both new-onset and refractory disease. Published consensus treatment plans are being implemented, facilitating studies of comparative effectiveness and toxicity.

KW - biomarkers

KW - consensus treatment plans

KW - corticosteroids

KW - morbidity

KW - mortality

KW - pathogenesis

KW - refractory disease

UR - http://www.scopus.com/inward/record.url?scp=84919815882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919815882&partnerID=8YFLogxK

U2 - 10.2217/ijr.14.46

DO - 10.2217/ijr.14.46

M3 - Article

AN - SCOPUS:84919815882

VL - 9

SP - 567

EP - 584

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1758-4272

IS - 6

ER -